SEPN
SEPN
NASDAQ · Pharmaceuticals

Septerna Inc

$36.08
+0.03 (+0.08%)
Financial Highlights (FY 2026)
Revenue
48.22M
Net Income
-51,298,964
Gross Margin
Profit Margin
-106.4%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 51.4% 51.4% 51.4%
Operating Margin -148.6% 37.7% 41.6% 40.2%
Profit Margin -106.4% 30.9% 31.1% 30.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 48.22M 203.59M 209.55M 172.61M
Gross Profit 104.74M 107.80M 88.80M
Operating Income -71,675,329 76.67M 87.11M 69.31M
Net Income -51,298,964 62.98M 65.23M 53.09M
Gross Margin 51.4% 51.4% 51.4%
Operating Margin -148.6% 37.7% 41.6% 40.2%
Profit Margin -106.4% 30.9% 31.1% 30.8%
Rev Growth +1.5% +13.6% +0.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 152.75M 171.86M 171.94M
Total Equity 626.19M 687.13M 754.44M
D/E Ratio 0.24 0.25 0.23
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -69,994,938 113.38M 119.42M 97.18M
Free Cash Flow 53.53M 45.52M 42.56M